Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease

Monday, September 24, 2007 General News
Email Print This Page Comment
FRAMINGHAM, Mass., Sept. 24 Iodine has been used as anantimicrobial for the last century. Much has been written about moleculariodine yet many women suffering from Fibrocystic Breast Disease (FBD) areunaware that studies being conducted may soon yield an effective nonhormonaltreatment.

While there are several breast cancer drugs on the market, all availablehormonal therapies have significant adverse events. In contrast, IoGen is anonhormonal treatment that allows for safe long-term use with little or noside effects.

"Current research provides substantive support for the initiation of humanclinical studies on the use of molecular iodine as a treatment for breastdisease," stated Paul Desjourdy, President and CEO, Symbollon Pharmaceuticals,Inc. "The possibility that IoGen may be used as a treatment for breast cancermakes it all the more important that we expedite the commercialization timeline."

The Company believes IoGen has the ability to eliminate excess cell growthin female reproductive tissue, including the breast, ovaries and uterus.Other indications for IoGen include the treatment or prevention ofendometriosis, ovarian cysts, and premenopausal breast cancer.

Symbollon Pharmaceuticals, Inc. is now in FDA Phase III clinical trialsfor the evaluation of IoGen (I2) for pain/tenderness associated with FBD andwith potential to treat female reproductive organ cancers.

The importance of (I2) in the treatments for mammary gland dysfunctionshas been corroborated in human and animal models.

Seaweeds, containing high quantities of iodine in several chemical formsincluding (I2), have been associated with low incidences of benign andmalignant breast disease in Asian women.

Past studies by independent researchers have supported the possibleeffectiveness of molecular iodine (I2) as a treatment for breast cancer.

Symbollon is now conducting its IoGen (I2) Phase III pivotal pain study.Results are expected in first quarter of 2008. For more information onIoGen(TM), please visit the company's web site at: www.symbollon.com/ orwww.mybreastpain.com.-- Researchers at Drexel University College of Medicine found that molecular iodine alters the gene expression profile in the human breast cancer cells. Dr. Bernard Eskin remarked that these changes may be responsible for molecular iodine's inhibition of breast cancer promotion that has been repeatedly observed in animal models. -- Some researchers investigating the connection between breast tissue and iodine observed that frequent childbirth and a long lactation period are known to reduce the risk of breast cancer.

SOURCE Symbollon Pharmaceuticals, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook